Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting [Yahoo! Finance]
Grace Therapeutics, Inc. (GRCE)
Company Research
Source: Yahoo! Finance
PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aSAH patients, today announced that results from its Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH (the STRIVE-ON trial– NCT05995405 ) were presented at the Neurocritical Care Society annual meeting, held in Montreal, Quebec, Canada September 18-21, 2025. In an oral presentation titled Safety and Tolerability of GTx-104 (Nimodipine Injection for I.V. Infusion) Compared with Oral Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage: a Prospective, Randomized Trial, Dr. H. Alex Choi (Professor of Neurosurgery and Neurology at UT Health Houston McGovern Medical School, member of the Grace Scientific Advisory Board.) highlighted the trial results d
Show less
Read more
Impact Snapshot
Event Time:
GRCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GRCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GRCE alerts
High impacting Grace Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GRCE
News
- Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select ConferenceGlobeNewswire
- Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business UpdateGlobeNewswire
- Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual MeetingGlobeNewswire
GRCE
Earnings
- 2/13/25 - Miss
GRCE
Sec Filings
- 11/17/25 - Form 10-Q/A
- 11/14/25 - Form SCHEDULE
- 11/13/25 - Form 8-K
- GRCE's page on the SEC website